Relief Mental Health expands trauma-informed psychiatric services in Wisconsin with appointment of Michael Henderson

Relief Mental Health, a leading U.S. outpatient behavioral healthcare provider specializing in transcranial magnetic stimulation (TMS), psychedelic therapy—including SPRAVATO esketamine and IV ketamine—psychiatric medication management, and psychotherapy, has added Michael Henderson, MSN, APNP, PMHNP-BC, to its West Allis, Wisconsin clinic. The move is expected to expand access to trauma-informed psychiatric services across the Milwaukee metropolitan area, strengthening the company’s footprint in the Midwest’s growing mental health treatment market.

Founded in January 2020, Relief Mental Health operates 11 clinics across Illinois, New Jersey, and Wisconsin, offering expedited access to care for patients with depression, obsessive-compulsive disorder (OCD), anxiety, and other complex psychiatric diagnoses. Henderson’s arrival reflects Relief’s strategic focus on recruiting specialized clinicians to meet increasing patient demand for advanced, evidence-based psychiatric treatments—especially in regions where wait times for mental health services can stretch for weeks or months.

Why Relief Mental Health is expanding its Wisconsin clinical team

The decision to bring Henderson on board comes amid heightened demand for outpatient behavioral health services in Wisconsin, a state where provider shortages have been a longstanding challenge. According to data from the Kaiser Family Foundation, over half of U.S. counties—including many in Wisconsin—have a shortage of mental health professionals. Relief Mental Health’s West Allis and Middleton clinics aim to bridge this gap by offering faster appointment scheduling, personalized medication management, and access to innovative treatment options like SPRAVATO.

Henderson’s addition aligns with sector-wide trends, where behavioral health operators are diversifying treatment modalities and expanding multidisciplinary care teams to address complex patient needs. Investors and healthcare analysts note that the post-pandemic period has seen accelerated adoption of treatments like esketamine and TMS, particularly as insurers broaden coverage for alternative psychiatric therapies.

Henderson’s trauma-informed expertise and veteran care background

As a board-certified psychiatric mental health nurse practitioner, Henderson brings specialized expertise in treating trauma-related disorders, including post-traumatic stress disorder (PTSD) and complex trauma. His clinical approach emphasizes safety, stabilization, and trust-building, foundational principles in trauma-informed care that are increasingly recognized as critical to improving patient engagement and outcomes.

Before joining Relief Mental Health, Henderson served at the VA Medical Center in Milwaukee, where he worked extensively with veterans—a population with higher incidences of PTSD, depression, and anxiety. At the VA, he developed individualized treatment plans, managed complex medication regimens, and provided patient education tailored to the unique needs of those who have experienced significant trauma. His work reinforced the importance of combining psychopharmacologic interventions with careful monitoring and supportive therapy.

Relief Mental Health CEO and leadership have underscored that Henderson’s background in veteran care is particularly valuable, as the Milwaukee area is home to a sizable veteran community. This appointment may also enhance Relief’s referral network with veteran service organizations, expanding access to specialized care.

SPRAVATO as a differentiator in treatment-resistant depression

One of Henderson’s key clinical offerings will be the administration of SPRAVATO (esketamine), an FDA-approved nasal spray for adults with treatment-resistant depression. Unlike traditional antidepressants, which primarily target serotonin pathways, SPRAVATO acts on the brain’s glutamate system, potentially delivering faster symptom relief. Clinical studies have shown that patients can experience improvement within hours or days, compared to weeks for conventional therapies.

Relief Mental Health integrates SPRAVATO into comprehensive care plans that include ongoing psychiatric evaluation, medication adjustment, and coordination with other therapies such as TMS. By offering multiple advanced treatment modalities under one roof, the West Allis clinic can tailor interventions to each patient’s response, which is a growing priority in precision psychiatry.

The company’s investment in esketamine services reflects broader market growth: Research firm Fortune Business Insights projects that the global ketamine treatment market will reach USD 3.9 billion by 2030, driven by rising mental health diagnoses and the limitations of existing antidepressant therapies.

A multidisciplinary, patient-centered model

Henderson’s role at Relief Mental Health extends beyond medication management. He will collaborate closely with a multidisciplinary team of psychiatrists, therapists, and TMS technicians to ensure care plans address the biological, psychological, and social dimensions of mental health. This integrated approach has been linked to better adherence, reduced relapse rates, and improved patient satisfaction.

The West Allis clinic’s coordination between pharmacologic interventions, psychotherapy, and neuromodulation therapies positions it as a comprehensive care hub. Henderson’s trauma-informed methodology complements this model by prioritizing patient trust, minimizing triggers, and creating a therapeutic environment conducive to recovery.

Mental health sector dynamics and investment interest

The expansion at Relief Mental Health’s West Allis site occurs against a backdrop of rising investor interest in outpatient behavioral health platforms. Private equity and healthcare REITs have increasingly targeted psychiatric clinic networks as demand surges and reimbursement models evolve. Analysts highlight that companies offering advanced interventions like TMS and esketamine are often seen as having a competitive advantage, given their ability to capture higher-acuity patient populations.

Relief Mental Health’s growth strategy mirrors moves by other multi-state behavioral health providers that are scaling through clinician recruitment and service diversification rather than solely through geographic expansion. This allows for deeper penetration into existing markets while maintaining brand recognition and clinical quality.

Strategic implications for Relief Mental Health in Wisconsin

By expanding its West Allis clinic’s capabilities with Henderson’s expertise, Relief Mental Health is better positioned to serve both urban and suburban Milwaukee patients, as well as those willing to travel from surrounding counties with limited psychiatric resources. The company’s two-location presence in Wisconsin also enables cross-clinic referrals and more efficient allocation of specialized services.

In a market where patient acquisition is increasingly driven by online search and physician referral networks, Relief’s ability to market specialized, trauma-informed care and advanced depression treatments could strengthen its competitive position. Given that the U.S. mental health services market is projected to exceed USD 150 billion by 2032, targeted clinician hires may be a cost-effective growth lever.

Expanding patient access and advancing treatment innovation

Henderson’s appointment signals Relief Mental Health’s commitment to combining clinical innovation with accessibility. Analysts expect that as more insurers expand coverage for treatments like SPRAVATO and TMS, demand will outpace current provider capacity. Clinics with specialized expertise and streamlined patient intake processes are likely to capture a larger share of this growth.

From an operational perspective, Relief’s focus on expedited care aligns with emerging best practices in psychiatric services, where early intervention is linked to better long-term outcomes. For patients in the Milwaukee area, Henderson’s arrival could mean faster access to care, more personalized treatment plans, and improved recovery trajectories.